| Literature DB >> 32283757 |
Mohamed M Abdel-Daim1,2, Samah R Khalil3, Ashraf Awad4, Ehsan H Abu Zeid3, Reda Abd El-Aziz5, Hamed A El-Serehy1.
Abstract
This study aimed to describe the protective efficacy of Moringa oleifera ethanolic extract (MOEE) against the impact of cobalt chloride (CoCl2) exposure on the rat's kidney. Fifty male rats were assigned to five equal groups: a control group, a MOEE-administered group (400 mg/kg body weight (bw), daily via gastric tube), a CoCl2-intoxicated group (300 mg/L, daily in drinking water), a protective group, and a therapeutic co-administered group that received MOEE prior to or following and concurrently with CoCl2, respectively. The antioxidant status indices (superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH)), oxidative stress markers (hydrogen peroxide (H2O2), 8-hydroxy-2-deoxyguanosine (8-OHdG), and malondialdehyde (MDA)), and inflammatory response markers (nitric oxide (NO), tumor necrosis factor (TNF-α), myeloperoxidase (MPO), and C-reactive protein (CRP)) were evaluated. The expression profiles of pro-inflammatory cytokines (nuclear factor-kappa B (NF-kB) and interleukin-6 (IL-6)) were also measured by real-time quantitative polymerase chain reaction (qRT-PCR). The results showed that CoCl2 exposure was associated with significant elevations of oxidative stress and inflammatory indices with reductions in the endogenous tissue antioxidants' concentrations. Moreover, CoCl2 enhanced the activity of the NF-κB inflammatory-signaling pathway that plays a role in the associated inflammation of the kidney. MOEE ameliorated CoCl2-induced renal oxidative damage and inflammatory injury with the suppression of the mRNA expression pattern of pro-inflammatory cytokine-encoding genes. MOEE is more effective when it is administered with CoCl2 exposure as a prophylactic regimen. In conclusion, MOEE administration exhibited protective effects in counteracting CoCl2-induced renal injury in rats.Entities:
Keywords: 8-hydroxy-2-deoxyguanosine; C-reactive protein; IL-6; Moringa oleifera; NF-κB; TNF-α; cobalt; myeloperoxidase
Mesh:
Substances:
Year: 2020 PMID: 32283757 PMCID: PMC7230732 DOI: 10.3390/nu12041031
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Scheme of procedure for preparation of Moringa oleifera ethanolic extract (MOEE).
Figure 2Experimental groups and treatments: MOEE: Moringa oleifera leave ethanolic extract (400 mg/kg body weight (bw), orally) and CoCl2: cobalt chloride (300 mg/L in drinking water).
Figure 3GC-MS based chemical profiling of MOEE.
Bioactive chemical constituents assigned in MOEE by GC-MS analysis.
| Bioactive Chemical Constituents | Chemical | Mass | Matching | Retention Time (RT) (min) | Area % |
|---|---|---|---|---|---|
| Eugenol: 4-allyl-2-methoxyphenol | C10H12O2 | 164 | 951 | 15.82 | 39.38 |
| α-Bisabolol | C15H26O | 222 | 877 | 25.09 | 15.00 |
| Bisabolol oxide B: 2-Furanmethanol,tetrahydro-à,à,5-trimethyl-5-(4-methyl-3-cyclohexen-1-yl)-, [2S-[2à,5á(R*)]]- | C15H26O2 | 238 | 927 | 23.08 | 6.19 |
| E-dipropylene glycol | C6H14O3 | 134 | 943 | 7.53 | 4.84 |
| Thymol: 2-isopropyl-5-methylphenol | C10H14O | 150 | 918 | 14.15 | 4.74 |
| Menthol: 1’-(butyn-3-one-1-yl)-, (1S,2S,5R)- 4-(1-Hydroxy-2-isopropyl-5-methylcyclohexyl)-3-butyn-2 -one | C15H24 | 204 | 701 | 21.70 | 3.41 |
| 2-(2-Hydroxypropoxy)-1-propanol | C6H14O3 | 134 | 950 | 7.62 | 3.30 |
| 7-Acetyl-6-ethyl-1,1,4,4-tetramethyltetralin | C18H26O | 258 | 930 | 27.34 | 2.78 |
| 2-Propanol,1,1-oxybis- | C18H32O2 | 134 | 892 | 7.10 | 2.67 |
| (-)-α-Bisabolol oxide A: 2H-Pyran-3-ol, tetrahydro-2,2,6-trimethyl-6-(4-methyl-3-cyclohexen-1-yl)-, [3S[3alpha,6alpha (R*)]] | C15H26O2 | 236 | 845 | 23.72 | 1.80 |
| 7a-Isopropenyl-4,5-dimethyloctahydroinden-4-yl)methanol | C15H26O | 222 | 816 | 23.26 | 1.53 |
| 2-phenylethanol | C8H10O | 122 | 921 | 9.29 | 1.39 |
| D- Carvone: 2-Cyclohexen-1-one, 2-methyl-5-(1-methylethenyl)- | C10H14O | 150 | 938 | 12.76 | 1.36 |
| Malonic acid: bis(1-methyl-2-hydroxyethyl)ether | C3H4O4 | 104 | 999 | 8.36 | 1.28 |
| Neophytadiene: 1,3-butadiene, 2-(4,8,12-trimethyltridecyl)- | C20H38 | 278 | 917 | 27.09 | 1.23 |
| (E)-Cinnamaldehyde: trans-3-phenyl-2-propenal | C9H8O | 132 | 871 | 13.47 | 1.04 |
| 1H-3a,7-Methanoazulene,2,3,6,7,8,8a-hexahydro-1,4,9,9-tetramethyl-(1à,3aà,7à,8aá)- | C15H24 | 204 | 868 | 18.28 | 0.97 |
| Phthalic acid: 1,2-Benzenedicarboxylic acid, diethyl ester | C12H14O4 | 222 | 942 | 20.06 | 0.96 |
| 1-Chloro-7-heptadecyne | C17H31Cl | 270 | 743 | 27.96 | 0.90 |
| 1-chlorotetradecane | C14H29Cl | 232 | 733 | 8.83 | 0.87 |
| Acetyl cedrene, Ethanone | C17H26O | 246 | 940 | 25.62 | 0.82 |
| Nerol: (Z)-3,7-dimethyl-2,6-octadien-1-ol | C10H18O | 154 | 907 | 13.11 | 0.80 |
| Methyl pimar-8-en-18-oate | C21H34O2 | 318 | 623 | 27.62 | 0.76 |
| Caryophyllene: Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R-(1R*,4E,9S*)]- | C15H24 | 204 | 888 | 17.39 | 0.68 |
| Alloaromadendrene: (1aS,4aR,7S,7aS,7bR)-1,1,7-Trimethyl-4-methylendecahydro-1H-cyclopropa[e]azulen | C15H24 | 204 | 907 | 18.37 | 0.65 |
| α-Isomethyl ionone: 4-(2,6,6-Trimethyl 2-cyclohexen-1-yl)-3-methyl-3-buten-2-one | C14H22O | 206 | 890 | 18.92 | 0.64 |
| 2-Pentadecanone, 6,10,14-trimethyl- | C18H36O | 268 | 876 | 27.21 | 0.43 |
Body weight change, relative kidney weight, kidney tissue injury markers, total protein variables in rats in response to MOEE administration (400 mg/kg body weight (bw), orally) and/or CoCl2 treatment (300 mg/L in drinking water).
| Parameters | Experimental Groups | ||||
|---|---|---|---|---|---|
| Control | MOEE | CoCl2 | MOEE/CoCl2+MOEE | CoCl2+MOEE /MOEE | |
| Body weight change (gm) | 12.00 b ± 1.09 | 18.16 a ± 1.44 | −11.00 d ± 0.73 | −5.00 c ± 2.67 | −8.00 cd ± 0.57 |
| Relative kidney weight | 0.25 ± 0.01 | 0.26 ± 0.01 | 0.27 ± 0.02 | 0.26 ± 0.02 | 0.28 ± 0.02 |
| Kidney tissue injury markers | |||||
| Urea (mg/dL) | 21.18 d ± 0.80 | 20.54 d ± 0.61 | 43.48 a ± 1.69 | 26.65 c ± 1.15 | 37.51 b ± 1.56 |
| Creatinine (mg/dL) | 0.83 d ± 0.02 | 0.84 d ± 0.04 | 1.97 a ± 0.06 | 1.09 c ± 0.05 | 1.49 b ± 0.06 |
| Protein profile | |||||
| Total protein (gm/dL) | 6.47 a ± 0.25 | 6.43 a ± 0.29 | 3.97 c ± 0.29 | 5.39 b ± 0.21 | 4.20 c ± 0.31 |
| Albumin (gm/dL) | 3.97 a ± 0.23 | 4.09 a ± 0.23 | 2.34 c ± 0.16 | 3.24 b ± 0.08 | 2.56 bc ± 0.22 |
| Globulin (gm/dL) | 2.49 a ± 0.09 | 2.35 a ± 0.13 | 1.63 b ± 0.15 | 2.15 ab ± 0.18 | 1.64 b ± 0.12 |
| A/G ratio | 1.60 ± 0.09 | 1.75 ± 0.11 | 1.46 ± 0.07 | 1.56 ± 0.14 | 1.56 ± 0.12 |
Means within the same row bearing different superscripts (a,b,c,d) are considered significantly varied (p ˂ 0.05) (mean ± SE). One-way ANOVA followed by Tukey’s B post hoc test. MOEE: Moringa oleifera leave ethanolic extract, CoCl2: Cobalt chloride-exposed group, MOEE/ CoCl2+MOEE: prophylaxis co-treated group, CoCl2 + MOEE/MOEE: therapeutic co-treated group.
Antioxidants and oxidative stress variables in rats in response to MOEE administration (400 mg/kg bw, orally) and/or CoCl2 treatment (300 mg/L in drinking water).
| Parameters | Experimental Groups | ||||
|---|---|---|---|---|---|
| Control | MOEE | CoCl2 | MOEE/CoCl2+MOEE | CoCl2 + MOEE /MOEE | |
|
| |||||
| SOD activity (U/gm tissue) | 3.77 a ± 0.31 | 3.82 a ± 0.23 | 1.63 c ± 0.19 | 2.48 b ± 0.12 | 1.81b c ± 0.20 |
| CAT activity (U/gm tissue) | 1.14 a ± 0.03 | 1.21 a ± 0.05 | 0.54 d ± 0.04 | 0.97 b ± 0.01 | 0.73 c ± 0.05 |
| GSH level (mmol/gm tissue) | 0.56 a ± 0.03 | 0.55 a ± 0.03 | 0.21 d ± 0.02 | 0.42 b ± 0.02 | 0.32 c ± 0.01 |
|
| |||||
| H2O2 (ng/mL) | 1.12 d ± 0.02 | 1.06 d ± 0.03 | 2.77 a ± 0.03 | 1.66 c ± 0.04 | 2.22 b ± 0.05 |
| MDA (nmoL/gm tissue) | 9.97 c ± 0.12 | 9.49 c ± 0.38 | 25.06 a ± 2.23 | 15.18 b ± 1.12 | 21.04 a ± 0.70 |
| 8OHdG (ng/mL) | 0.09 d ± 0.01 | 0.07 d ± 0.01 | 0.37 a ± 0.02 | 0.16 c ± 0.01 | 0.31 b ± 0.01 |
Means within the same row bearing different superscripts (a,b,c,d) are considered significantly varied (p ˂ 0.05) (mean ± SE). One-way ANOVA followed by Tukey’s B post hoc test. MOEE: Moringa oleifera leave ethanolic extract, CoCl2: Cobalt chloride-exposed group, MOEE/ CoCl2 + MOEE: prophylaxis co-treated group, CoCl2 + MOEE/MOEE: Therapeutic co-treated group, 8OHdG: 8-hydroxy-2-deoxyguanosine, CAT: catalase, GSH: glutathione, SOD: superoxide dismutase.
Figure 4Inflammatory markers (nitric oxide, NO; tumor necrosis factor-α, TNF-α; myeloperoxidase, MPO; and C-reactive protein, CRP) in the kidney tissue of rats in response to MOEE administration (400 mg/kg bw, orally) and/or CoCl2 treatment (300 mg/L in drinking water). Bars carrying different letters (a, b, c, d, e) are significantly differently (p ˂ 0.05) (mean ± SE). One—way ANOVA followed by Tukey B post hoc test. MOEE: Moringa oleifera leave ethanolic extract-administered group, CoCl2: Cobalt chloride-exposed group, MOEE/ CoCl2 + MOEE: prophylaxis co-treated group, CoCl2 + MOEE/MOEE: therapeutic co-treated group.
Figure 5Relative expression of nuclear factor-kappa B (NF-kB) and interleukin (IL)-6 mRNA in the kidney tissue of rats in response to MOEE administration (400 mg/kg bw, orally) and/or CoCl2 treatment (300 mg/L in drinking water). The expression abundance of genes mRNA was normalized against the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) internal control gene. Bars carrying different letters (a, b, c) are significantly different (p ˂ 0.05) (mean ± SE). One-way ANOVA followed by Tukey B post hoc test. MOEE: Moringa oleifera leave ethanolic extract-administered group, CoCl2: Cobalt chloride-exposed group, MOEE/CoCl2 + MOEE: prophylaxis co-treated group, CoCl2 + MOEE/MOEE: therapeutic co-treated group.